Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCLA L-08: Necitumumab, Trastuzumab, and Osimertinib in Refractory EGFR-Mutated NSCLC
NCT04285671Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of necitumumab, trastuzumab in non-small cell lung cancer (NSCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jan 2021; status: active, not recruiting.
02
Drugs
necitumumabtrastuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04285671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04285671.